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3 possesses potent micro-molar anticancer 
activity.  A membrane interactive process,
combining attractive London dispersion and
Coulombic forces, to help lyse the cell 
membrane, is proposed.
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The pyridinium salts, 12-methacryloyloxydodecylpyridinium 
bromide (MDPB) and cetylpyridinium chloride (CPC, Fig. 1), 
have been identified as potent cytotoxic agents and have been 
extensively used in the dental profession for the treatment of oral 
infections.1 The cytotoxic mechanism of such quaternary 
ammonium compounds is believed to be due to the cationic 
pyridinium salts binding to negatively charged cell wall 
components. Consequently, this disturbs the membranes’ 
electrical balance, and subsequently induces leakage of 
cytoplasmic material leading to cell death,2-4 a process which is 
presumably aided by the alkyl chains of MDPB and CPC 
penetrating and disrupting the hydrophobic lipid bilayer of the 
cell membrane simultaneously. Moreover, the associated drugs, 
perifosine and miltefosine (Fig. 1), which are structurally related 
to the phospholipid components of the cell membrane, are 
thought to exert their antineoplastic actions by disruption of cell-
membrane function and thus they display significant anti-
proliferative activity in vitro and in vivo in several human tumour 
model systems and leishmaniasis.5,6  
In a mechanistically similar manner to such compounds, it has 
recently been demonstrated that certain aromatic molecules with 
a defined shape, and which are suitably adorned with long alkyl 
chains, behave similarly in being able to disturb lipid membranes 
(1, Fig. 1),7,8 but that, due to their distinctive three-dimensional 
shape, which places the two benzene rings adjacent to each other, 
are able to donate the two alkyl chains at the same time, thus 
potentially exert twice the membrane-disrupting capability to that 
of MDPB, CPC, perifosine and miltefosine at the same 
concentrations. Unfortunately, with such compounds (i.e. 1), the 
high hydrophobicity and thus poor water solubility somewhat 
limits their use as biocidal agents. 
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Figure 1. The structures of MDPB, CPC, perifosine, miltefosine and 
the experimental compounds 1-3. 
It was anticipated that the preparation of 3 would generate an 
amphiphilic compound that is structurally related to the known 
compounds shown in Fig. 1, but one that contains two charges 
and two alkyl chains, effectively doubling the interactions 
between the compound and the membrane. Additionally, the 
charges may also aid in the aqueous solubility of these 
compounds, a feature which has been problematic with similar 
compounds such as 1. Fig. 2 depicts a schematic representation 
of the proposed interactions expected between 3 and negatively 
charged membranes – thus ultimately causing membrane 
destabilization, lysis and a potential treatment for disease. 
Xx 
Figure 2. A schematic depicting the proposed interaction of 
positively charged 3 with a negatively charged lipid monolayer. 
The synthesis of compound 1 has been previously reported by 
us
7
 and the synthesis of compounds 2 and 3 are outlined in 
Scheme 1. 
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Scheme 1. The synthesis of compounds 2 and 3. 






The synthesis and biological evaluation of a novel pyridinium salt is reported. Initial membrane 
interaction with isolated phospholipid monolayers was obtained with the pyridinium salt, and 
two neutral analogues for comparison, and the anticancer effects of the best compound 
established using a cytotoxicity screening assay against glioma cells using both an established 
cell line and three short-term cell cultures – one of which has been largely resistant to all 
chemotherapeutic drugs tested to date. The results indicate that the pyridinium salt exhibits 
potent anticancer activity (EC50s = 9.8-312.5 µM) on all cell types, including the resistant one, 
for a continuous treatment of 72 hours. Microscopic examination of the treated cells using a 
trypan blue exclusion assay showed membrane lysis had occurred. Therefore, this letter
highlights the potential for a new class of pyridinium salt to be developed as a much needed 
alternative treatment for glioma chemotherapy. 










Briefly, a successful union between N-methyl-4-pyridinamine 
(4) and isonicotinoyl chloride (5) was achieved in high yield 
(90% after purification) to generate the desired N-methylated 
amide product, 2. Subsequent bis-alkylation of 2 was then 
achieved in high yield (88% after purification) with an excess of 
n-octyliodide to provide 3. 
Xx 
Figure 3. Percentage membrane lysis of calcein-entrapped vesicles 
made up of DMPG (A), DMPE (B), DMPS (C) and DMPC (D). 
Grey circles = 1, black crosses = 2 and grey crosses = 3, where n=5 
with error bars showing standard deviation. DMPG = 
dimyristoylphosphatidylglycerol, DMPE = 
dimyristoylphosphatidylethanolamine, DMPS =   
dimyristoylphosphatidylserine and DMPC = 
dimyristoylphosphatidylcholine. 
Having the compounds to hand, their ability to lyse 
membranes of calcein-entrapped vesicles was determined. As can 
been seen from Fig. 3, all membranes [DMPG (A), DMPE (B), 
DMPS (C) and DMPC (D)] are lysed to similar maximal levels 
(~60-80%); however, each of the three compounds 1-3 lyse the 
four membranes to differing extents, but always with the same 
order of activity for each compound, demonstrating the 
dependence of the release on the vesicle membrane composition, 
as has been shown in related work with CPC.9 For example, all 
membranes are lysed to the greatest extent with 3, whilst the 
lowest levels of membrane lysis are brought about by 2, making 
the activity of 1 somewhere in between. Gratifyingly, this 
correlates exactly with what was expected with regard to the 
working hypothesis depicted in Fig. 2, in that the neutral 
compound 2, which lacks any alkyl groups, interacts more 
weakly with all the membranes giving rise to a maximum lysis of 
~40-50%. Presumably, at the pH of the lysis experiments, enough 
protonation of the pyridine nitrogen’s in 2 can occur, meaning 
that this (now pyridinium) compound can interact with the polar 
lipid head groups and H-bond to unprotonated molecules of 2 
thus associate at the lipid surface, thus causing some disruption 
of the lipid packing and its electrical balance, but since it lacks 
the alkyl groups, 2 cannot penetrate deeply into the membrane 
and cause maximal membrane damage. Conversely, the neutral 
compound 1, which does contain the lipid-penetrating alkyl 
groups, but is uncharged, is able to interact better with the 
hydrophobic lipid chains, but it cannot interact strongly with the 
polar headgroups, thus resulting in a maximum membrane lysis 
of ~60-70%. However, the charged compound (3) presumably 
experiences a greater attractive force to the negatively charged 
components of the membranes, as well as possessing the lipid-
penetrating alkyl groups thus resulting in a percentage lysis range 
of 70-80%. Moreover, although the concentration range was 
extended into milli-molar values to obtain the plateau at which 
maximal lysis occurs, it should be noted that that gradient of the 
curves at micro-molar concentrations is steep enough to give rise 
to similar values of membrane lysis to the maximal values 
obtained (i.e. the plateau of membrane lysis occurs quickly and at 
micro-molar concentrations in most cases); as such, for a direct 
comparison at a single concentration, Table 1 outlines the percent 
lysis obtained at 187.5µM. As can be seen, compound 3 is able to 
lyse all four lipids studied to the highest levels, whereas 
compound 2 is equipotent to 1 against DMPE, DMPS and 
DMPC, but is able to lyse almost twice as much of the liposomes 
composed of DMPG than 1, suggesting that charge (under the 
experimental conditions) is more dominant than the alkyl chains; 
a facet supported by the structure of 3, which has both. 
Moreover, whilst the liposomes composed of lipids 
representative of mammalian cancer cells (DMPC),10 were only 
lysed to ~39% with 3, those liposomes composed of the main 
constituent lipid from E. coli cells (DMPE) were lysed by ~80% 
with 3,10 suggesting that future studies of this compound could be 
important in the development of new antimicrobial agents, 
especially since it has been shown that alkyl chain length can be 
tuned to optimise membrane perturbation,11 and control the mode 
of action as well.12 
Table 1. Calcein release assay: percentage calcein release for 
compounds 1-3 against the four lipid vesicles. The values shown are 
the average and standard deviations of five experiments at a single 
concentration of 187.5µM. 
Compound DMPG DMPE DMPS DMPC 
1 16.6±5.7 34.7±1.3 27.2±2.6 27.3±0.1 
2 30.0±5.4 34.9±0.9 23.3±2.1 34.1±0.2 
3 44.2±6.8 77.7±2.9 64.6±2.1 38.8±0.2 
 
Based on these encouraging results, and in continuation of our 
efforts to try and develop new treatments for malignant brain 
tumours, it was of interest to us to determine what effects the 
most potent compound (3) has against glioma cells available to 
us through the Brain Tumour North West alliance.13 
Three short-term cultures (IN1528, IN1760 and IN1472) and 
one established cell line (U251-MG) were used in this study to 
determine the potential anti-proliferative effects of the best 
membrane-interactive compound (3) on whole cells using a 
sulphorhodamine-B assay. The neutral compound (1) was shown 
to precipitate from the media and was not used further – 
presumably, the different media used in the calcein and 
cytotoxicity assays, largely additional amino acids, vitamins, 
inorganic salts and other components, causes the differing 
solubilities of 1 in the two assays. A range of concentrations of 
the test compound (1-5000µM, in triplicate) were screened and 
the EC50s determined (Table 2). Compound 3 inhibited 
proliferation in all GBM cells studied at low (micro-molar) 
levels, particularly in the short-term cultures which are more 
representative of primary tumours in vivo. Importantly, 
compound 3 was also shown to be extremely potent against the 
highly resistant cell culture IN1760, a culture which has proved 
to be highly resistant to a number of commercially available 
anticancer drugs (CCNU, vincristine and doxorubicin),14 
indicating that this class of molecule holds potential for further 
development as a glioma therapy of the future. 
Table 2. EC50 values of compound 3 against various glioma cells. 






 EC50 is the 50% effective concentration of compound 3 which 
induces a response halfway between the baseline and maximum 
values after 72 h. 
Having determined the anticancer activity of pyridinium salt 3 
on all glioma cell cultures examined, the exact mechanism of cell 
death was briefly probed. A dye exclusion assay, using the dye 
trypan blue, was performed to detect any membrane lysis that 
might be occurring early on post-treatment. In separate 
experiments, all cell cultures were studied microscopically, 
whereby it was observed that at both 200 and 500µM of 
compound 3, the cells stained positive for trypan blue, as 
  
indicated by the ready uptake of the dye, suggesting that 3 is able 
to compromise the cell membrane and enable the dye to pass 
through, but at these concentrations there is not enough of it 
accumulating at the cell surface to completely obliterate the cells 
(see Supp. Info.). Conversely, for comparison, at 1000µM the 
cells appeared completely obliterated and there was no cell 
structure remaining to contain the trypan blue dye. 
Together the above data suggests that at certain micro-molar 
concentrations (Fig. 3 and Table 1) compound 3 is present at the 
membrane in sufficient concentrations to be able to bind to it 
through an initial electrostatic interaction with the lipid 
headgroups, and following insertion in to the membrane, cause it 
to become compromised. The elucidation and concentration 
effects of the exact molecular pathways employed by this 
pyridinium salt in glioma cells, as well as aqueous solubility 
optimisation studies are the focus of an on-going study. 
In conclusion, the synthesis and biological evaluation of a 
novel pyridinium salt (3) has been reported which combines the 
favourable features of 1 (possessing two lipid-penetrating alkyl 
chains) and 2 (possessing two positive charges when subjected to 
the experimental conditions). Interactions with both isolated 
phospholipid monolayers and glioma cells were obtained with the 
pyridinium salt and two neutral analogues. The results indicate 
that the pyridinium salt (3) exhibits potent anticancer activity 
(EC50s = 9.8-312.5 µM) on all cell types, including a resistant 
one, and a trypan blue dye exclusion assay suggests that the exact 
mechanism of cell death is due to membrane lysis. Due to the 
known differing lipid composition of cancer cells versus healthy 
mammalian cells, compound 3 and its prospective analogues, 
may present a promising approach to selectively target cancer 
cells and thus have the potential to be developed further into 
alternative treatments for glioma chemotherapy in the future. 
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compound 3 into the monolayer
Attractive London dispersion forces
between lipid and alkyl chains
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